When a peptide telehealth platform tells you your prescription is "compounded by a 503A pharmacy," that phrase is doing real work. It means something specific about how your medication is made, who's overseeing the process, and what regulations apply. Here's the plain-English version.
What "compounded" actually means
Compounding is the practice of preparing a medication for an individual patient — combining, mixing, or altering ingredients to create something tailored to that patient's needs. It's been part of pharmacy practice for centuries, going back to the era when every pharmacist measured out medications by hand from raw ingredients.
Today, most pharmaceuticals are mass-manufactured by drug companies and sold off the shelf. But for many therapeutic peptides — and other categories where one-size-fits-all dosing doesn't fit — compounded medications are still how patients get their prescriptions filled. A licensed pharmacy prepares a custom formulation pursuant to a physician's order.
The two compounding categories
The Federal Food, Drug, and Cosmetic Act (FDCA) defines two distinct types of compounding pharmacies under sections 503A and 503B. They sound similar. They're not.
503A — patient-specific compounding
A 503A pharmacy compounds medications for individual patients in response to a valid prescription from a licensed prescriber. Each formulation is patient-specific. The pharmacy is regulated primarily by its state board of pharmacy, with federal compounding standards (USP <795> for non-sterile, USP <797> for sterile) applying to the practice.
Key characteristics:
- Compounding is done in response to a valid prescription for an individual patient
- The pharmacy generally cannot prepare large batches in advance "for office use"
- State board of pharmacy is the primary regulator
- Federal exemptions from certain FDA requirements apply when the pharmacy operates within 503A bounds
Most peptide telehealth platforms, including Lior, work with 503A pharmacies. The patient-specific model fits how peptide therapy actually works clinically — your physician decides on a dose, the pharmacy compounds it for you, that batch is yours.
503B — outsourcing facilities
A 503B outsourcing facility is a different category created by the Drug Quality and Security Act of 2013. 503B facilities can compound medications in larger batches without patient-specific prescriptions, generally for distribution to healthcare facilities (hospitals, clinics, infusion centers) that need on-hand inventory.
Key characteristics:
- Can compound in larger volumes for "office use" without per-patient prescriptions
- Subject to FDA inspection and full Current Good Manufacturing Practice (CGMP) standards similar to drug manufacturers
- Must register annually with the FDA
- Held to higher manufacturing-quality standards than 503A but with a more limited compounding scope (cannot compound non-bulk-listed substances)
503B is closer to a drug manufacturer in regulatory terms. 503A is closer to traditional pharmacy practice.
503A = "this prescription was made for you, by your name, today." 503B = "this batch was made under FDA-grade manufacturing for a clinic to keep on hand." Both are legitimate. Both have their place. Most peptide telehealth lives in the 503A world because the model is one-physician-one-patient-one-prescription.
Why this matters for patients
If you're getting a peptide protocol from a telehealth platform and the platform won't tell you which pharmacy is preparing your medication or under what regulatory framework — that's a red flag. Legitimate operators are transparent about their pharmacy chain. Grey-market operators tend to be vague.
Things to look for:
- Named pharmacy partner. Your platform should be willing to tell you which pharmacy is compounding your medication.
- 503A or 503B identification. The pharmacy should clearly identify under which framework it operates.
- State board licensure. The pharmacy should be licensed in good standing with its state board of pharmacy.
- Certificate of Analysis (CoA) availability. Higher-quality 503A pharmacies provide third-party potency, sterility, and endotoxin testing on their compounded products. You should be able to request a CoA for your prescription.
- US-based operation. The pharmacy should be a US-based operation operating under US compounding law.
Compounded medications and FDA approval
An important point that's often misunderstood: compounded medications are not FDA-approved. The FDA approves manufactured drugs through a defined process involving clinical trials and manufacturing review. Compounded medications, by definition, are prepared on a patient-specific basis pursuant to a valid prescription — not mass-manufactured under FDA approval.
This is legal. It's how compounding has worked for decades. But patients should understand the distinction. A compounded version of Semaglutide is not the same product as Wegovy, even if the active ingredient is the same. Wegovy went through FDA's approval process; the compounded version did not.
Why use compounded versions, then? In some cases, the FDA-approved version isn't accessible (shortage, insurance), the dosing isn't right for the individual patient, or a specific formulation matters. A licensed prescriber makes that judgment call patient-by-patient.
Where Lior fits in
Lior Health works exclusively with 503A-licensed US compounding pharmacies. Our pharmacy partners are state-board-regulated, transparent about their licensure, and provide certificates of analysis on request.
Every Lior protocol is patient-specific: a US-licensed physician writes the prescription based on your assessment, the 503A pharmacy compounds the formulation specifically for you, and it ships directly to your door. There's no "office stock," no bulk batches, no opaque sourcing.
If you want to dig deeper, our peptide therapy primer covers the broader category, and our GLP-1 explainer covers the metabolic-protocol class specifically.